Third-Party Tested by Verum Analytics
CJC-1295 + Ipamorelin
Research blend combining CJC-1295 (No DAC) and Ipamorelin for comparative GHRH receptor studies.
Third-Party Tested by Verum Analytics
Albert's Verdict
Stacking CJC-1295 without DAC with Ipamorelin gives you GHRH and GHS-R1a stimulation on two distinct pathways simultaneously. The pulse amplitude data on pituitary secretion from this combination is consistently stronger than either compound in isolation.
View COA✓ In stock - Ships same day
Arrives as lyophilized (powder) form
Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.
Product Description
CJC-1295 + Ipamorelin Blend pairs a GHRH analog (Modified GRF 1-29) with a selective GHS-R1a ghrelin-receptor agonist for comparative GHRH-axis receptor research. The two compounds act on distinct pituitary receptor pathways and are commonly studied together in receptor-crosstalk and pulse-frequency models.
Blend Composition:
- CJC-1295 (No DAC): GHRH analog (Modified GRF 1-29)
- Ipamorelin: Selective GHS-R1a pentapeptide agonist
Research Applications:
- Comparative GHRH × GHS-R1a receptor signaling studies
- IGF-1 axis modulation research
- GHRH pulse amplitude and frequency analyses
- Receptor selectivity and downstream signaling investigations
Quality Standards:
- Each component: ≥99% purity verified by HPLC
- Third-party tested with COA included
FOR RESEARCH AND LABORATORY USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Technical Specifications
- Molecular Formula
- C152H252N44O42 + C38H49N9O5
- Molecular Weight
- 3367.97 + 711.85 g/mol
Frequently Researched Together
Commonly studied alongside in laboratory settings
Learn More About This Peptide
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.